Pharsight to Present on Literature-Based Disease Modeling Approaches at AAPS National Biotechnology Conference
June 17 2008 - 5:30AM
PR Newswire (US)
Dr. Farkad Ezzet Will Present on the Strategic Value of Literature
Modeling to Assess Disease Progression and Drug Attributes in
Clinical Development MOUNTAIN VIEW, Calif., June 17
/PRNewswire-FirstCall/ -- Pharsight Corporation (NASDAQ:PHST), a
leading provider of software, strategic consulting, and regulatory
services for optimizing clinical drug development, today announced
that Farkad Ezzet, Ph.D., senior scientist, Pharsight Strategic
Consulting Services, has been invited to speak to members of the
biotechnology and pharmaceutical industries attending the 2008 AAPS
National Biotechnology Conference. The Congress will be held at the
Metro Toronto Convention Center in Toronto, Canada from June 22-25,
2008. Dr. Ezzet will present on June 24, joining other leading
industry experts in a roundtable session on the utilization of
disease progression models in clinical drug development. Dr.
Ezzet's presentation, entitled "The Role of Literature-Based
Disease Progression Models to Support Knowledge Management and
Decision-Making in Clinical Drug Development," will describe how
model-based approaches that incorporate public-source data from the
scientific literature can provide quantitative insights into
disease progression and predictive assessments of a new drug
candidate's likely product profile versus competing treatments. Dr.
Ezzet's presentation will feature an illustrative case study for
the treatment of obesity, and will also cover important
considerations for using literature-based modeling approaches to
enhance strategic decision-making in drug development.
"Literature-based models provide a quantitative assessment of the
competitive landscape and offer a framework to address important
clinical development program questions," said Shawn O'Connor,
president, CEO, and chairman of Pharsight. "Public domain
information and data can be leveraged to develop candidate disease
models, to measure the performance of established treatments across
target therapeutic areas, and to help predict the likely clinical
profile of early-stage development compounds. Pharsight is pleased
to participate at the AAPS roundtable session, and we look forward
to sharing our perspective with industry colleagues on the
strategic use of modeling and simulation to enhance drug
development decision-making." Further information can be found at
http://www.aapspharmaceutica.com/meetings/biotec/bt08. About
Pharsight Corporation Pharsight Corporation develops and markets
integrated products and services that enable pharmaceutical and
biotechnology companies to achieve significant and enduring
improvements in the development and use of therapeutic products.
Pharsight's goal is to help customers reduce the time, cost and
risk of drug development, as well as optimize the post-approval
marketing and use of pharmaceutical products. Pharsight's approach
enhances the fundamental element of drug development success:
strong decision-making. By adopting the Pharsight approach,
customers acquire a new decision-making process with the potential
to systematically improve every level and phase of their business
and scientific processes. Pharsight Corporation is headquartered in
Mountain View, California. Information about Pharsight is available
at http://www.pharsight.com/. Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All
other brand or product names mentioned in this documentation are
trademarks or registered trademarks of their respective companies
or organizations. DATASOURCE: Pharsight Corporation CONTACT: Media,
Steve DiMattia or Donald Takaya, +1-646-201-5445, or Investors,
Douglas Sherk or Matthew Selinger, +1-415-896-6820, all of EVC
Group for Pharsight Corporation Web site: http://www.pharsight.com/
http://www.aapspharmaceutica.com/meetings/biotec/bt08
Copyright
Pharsight Corp (MM) (NASDAQ:PHST)
Historical Stock Chart
From Dec 2024 to Jan 2025
Pharsight Corp (MM) (NASDAQ:PHST)
Historical Stock Chart
From Jan 2024 to Jan 2025
Real-Time news about Pharsight Corp (MM) (NASDAQ): 0 recent articles
More Pharsight (MM) News Articles